Prescribing overview
An equine injectable reversal agent for xylazine-induced sedation and analgesia.
Reversal restores alertness but also removes xylazine’s pain relief. Decide whether the horse still needs analgesia before reversal, and maintain observation rather than assuming rapid arousal means a complete recovery. The U.S. indication is specifically xylazine reversal.
Key prescribing checks
- Review the source-specific safety card and monitoring plan before use.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Horses
U.S. labeled/regulatory equine use; see exact scopeReversal of sedation and analgesia caused by xylazine
U.S. equine indication; not a blanket reversal authorization for other sedatives or species.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Adrenergic antagonism counteracts xylazine. FDA approval studies demonstrated changes in sedation and analgesic response after intravenous administration.
Absorption, distribution, metabolism and elimination
FDA’s original evaluation describes relatively rapid elimination in healthy ponies without other drugs; this does not establish behavior in unstable patients.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Tolazine
U.S. equine Tolazine indication; FDA approval evaluation and manufacturer information.
Contraindications · when not to use
A formal contraindication list is not established in the reviewed source for this scope. This does not establish safety; confirm the exact product and full labeling.
Precautions & monitoring
- Manufacturer precautions advise against administration in stressed, debilitated or cardiac-compromised animals; verify the complete current insert before use.
- Safety in pregnant/lactating or breeding mares and foals is unestablished. Not for food-producing animals.
This is a selected source summary, not exhaustive prescribing guidance.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Vasodilation, tachycardia, restlessness, sweating, muscle fasciculations and gastrointestinal hypermotility or discomfort were observed in approval studies.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No numerical regimen is reproduced. Verify current label, prior xylazine administration, patient status and administration rate.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Tolazine
U.S. equine Tolazine indication; FDA approval evaluation and manufacturer information.
- Intended to reverse xylazine; reversal of a multi-agent anesthetic protocol needs a separate assessment. A complete interaction list is not established by the approval summary.
Monitoring
Observe cardiovascular status, demeanor, intestinal comfort and recovery of safe coordination after administration.
Client counseling
Pain may return as sedation is reversed. Handling precautions remain necessary during recovery.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Follow the current finished-product container storage instructions; use careful injectable handling and avoid accidental human exposure.
Brands, formulations & ingredient identity
Active ingredients
Tolazoline hydrochloride
Other searchable names: Tolazine
Tolazine is the reviewed equine injectable product. Bulk tolazoline listings are not equivalent finished-product approval.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Tolazine
- Formulation
- Tolazoline hydrochloride injection
- Label / product scope
- Horses
Slow intravenous administration under veterinary supervision.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
